OBJECTIVES AND METHODS: This study explored whether C-reactive protein (CRP) and/or procalcitonin levels were useful to measure vaccine efficacy (VE) and impact against the burden of pneumonia of a 9-valent pneumococcal conjugate vaccine (PCV), compared with chest radiograph-confirmed alveolar consolidation (CXR-AC) as an outcome. Sera obtained from children participating in a phase 3 PCV efficacy trial who were hospitalized for treatment of clinically diagnosed lower respiratory tract infection (C-LRTI) were retrospectively analyzed for CRP and procalcitonin measurements. RESULTS: For non-human immunodeficiency virus (HIV)-infected children, the VE estimates for C-LRTI with CRP levels of > or =40 mg/dL (VE 26.3%; P = 0.003) or CRP levels of > or =120 mg/dL (VE 41.0%; P = 0.003) were 1.7-fold (P = 0.002) and 2.7-fold (P < 0.0001) greater, respectively, than that for CXR-AC (VE 15.1%; P= 0.15). The sensitivity of CXR-AC as an outcome to detect the burden of pneumonia prevented by PCV was 44% (95% confidence interval, 36-55%) in comparison with C-LRTI with CRP levels of > or =40 mg/dL and 73% (95% confidence interval, 58-92%) in comparison with C-LRTI with CRP levels of > or =120 mg/dL. CRP also helped to measure the PCV efficacy for children with C-LRTI but the absence of CXR-AC, for whom the outcome of C-LRTI with CRP levels of > or =40 mg/dL (VE 31.5%; P = 0.007) increased the VE estimate 19.8-fold (P < 0.0001) in comparison with C-LRTI alone (VE 1.6%; P = 0.78) and 3.2-fold (P = 0.005) in comparison with WHO-defined severe pneumonia (VE 10.0%; P = 0.17). Although there was a significant correlation between CRP and procalcitonin levels (Spearman's rho = 0.45; P < 0.0001), the use of procalcitonin levels did not improve either the specificity or sensitivity of measuring the effect of PCV against pneumonia for non-HIV-infected children. The observations were similar for HIV-infected children. CONCLUSIONS:CRP levels of > or =40 mg/dL provide a better measure than chest radiographs to assess the effect of PCV in preventing pneumonia.
RCT Entities:
OBJECTIVES AND METHODS: This study explored whether C-reactive protein (CRP) and/or procalcitonin levels were useful to measure vaccine efficacy (VE) and impact against the burden of pneumonia of a 9-valent pneumococcal conjugate vaccine (PCV), compared with chest radiograph-confirmed alveolar consolidation (CXR-AC) as an outcome. Sera obtained from children participating in a phase 3 PCV efficacy trial who were hospitalized for treatment of clinically diagnosed lower respiratory tract infection (C-LRTI) were retrospectively analyzed for CRP and procalcitonin measurements. RESULTS: For non-human immunodeficiency virus (HIV)-infectedchildren, the VE estimates for C-LRTI with CRP levels of > or =40 mg/dL (VE 26.3%; P = 0.003) or CRP levels of > or =120 mg/dL (VE 41.0%; P = 0.003) were 1.7-fold (P = 0.002) and 2.7-fold (P < 0.0001) greater, respectively, than that for CXR-AC (VE 15.1%; P= 0.15). The sensitivity of CXR-AC as an outcome to detect the burden of pneumonia prevented by PCV was 44% (95% confidence interval, 36-55%) in comparison with C-LRTI with CRP levels of > or =40 mg/dL and 73% (95% confidence interval, 58-92%) in comparison with C-LRTI with CRP levels of > or =120 mg/dL. CRP also helped to measure the PCV efficacy for children with C-LRTI but the absence of CXR-AC, for whom the outcome of C-LRTI with CRP levels of > or =40 mg/dL (VE 31.5%; P = 0.007) increased the VE estimate 19.8-fold (P < 0.0001) in comparison with C-LRTI alone (VE 1.6%; P = 0.78) and 3.2-fold (P = 0.005) in comparison with WHO-defined severe pneumonia (VE 10.0%; P = 0.17). Although there was a significant correlation between CRP and procalcitonin levels (Spearman's rho = 0.45; P < 0.0001), the use of procalcitonin levels did not improve either the specificity or sensitivity of measuring the effect of PCV against pneumonia for non-HIV-infectedchildren. The observations were similar for HIV-infectedchildren. CONCLUSIONS:CRP levels of > or =40 mg/dL provide a better measure than chest radiographs to assess the effect of PCV in preventing pneumonia.
Authors: J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland Journal: J Clin Invest Date: 2008-04 Impact factor: 14.808
Authors: K F O'Grady; J B Carlin; A B Chang; P J Torzillo; T M Nolan; A Ruben; R M Andrews Journal: Bull World Health Organ Date: 2009-12-08 Impact factor: 9.408
Authors: Carrie Reed; Shabir A Madhi; Keith P Klugman; Locadiah Kuwanda; Justin R Ortiz; Lyn Finelli; Alicia M Fry Journal: PLoS One Date: 2012-01-04 Impact factor: 3.240
Authors: Jennifer D Loo; Laura Conklin; Katherine E Fleming-Dutra; Maria Deloria Knoll; Daniel E Park; Jennifer Kirk; David Goldblatt; Katherine L O'Brien; Cynthia G Whitney Journal: Pediatr Infect Dis J Date: 2014-01 Impact factor: 2.129
Authors: Claudia Turner; Paul Turner; Verena Cararra; Naw Eh Lwe; Wanitda Watthanaworawit; Nicholas P Day; Nicholas J White; David Goldblatt; François Nosten Journal: PLoS One Date: 2012-11-20 Impact factor: 3.240
Authors: Claudia Turner; Paul Turner; Verena Carrara; Kathy Burgoine; Saw Tha Ler Htoo; Wanitda Watthanaworawit; Nicholas P Day; Nicholas J White; David Goldblatt; François Nosten Journal: PLoS One Date: 2013-01-08 Impact factor: 3.240
Authors: Laura K Erdman; Valérie D'Acremont; Kyla Hayford; Nimerta Rajwans; Mary Kilowoko; Esther Kyungu; Philipina Hongoa; Leonor Alamo; David L Streiner; Blaise Genton; Kevin C Kain Journal: PLoS One Date: 2015-09-14 Impact factor: 3.240
Authors: Momanna B Ahmed; Kanan Patel; Gregg C Fonarow; Charity J Morgan; Javed Butler; Vera Bittner; Andrzej Kulczycki; Raya E Kheirbek; Wilbert S Aronow; Ross D Fletcher; Cynthia J Brown; Ali Ahmed Journal: ESC Heart Fail Date: 2015-09-21